Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Fertility Preservation- Oncology Treatment Effects and Psychological Impact

27 oktober 2021 uppdaterad av: Weill Medical College of Cornell University
The purpose of this study is assess the effects of oncology treatment on ovarian reserve and also to better understand the experiences, thoughts and feelings of women scheduled to undergo chemotherapy/radiotherapy and seeking fertility preservation at Weill Cornell Medical College (WCMC).

Studieöversikt

Status

Avslutad

Betingelser

Intervention / Behandling

Detaljerad beskrivning

This will be a prospective, non-randomized, uncontrolled study examining the effects of oncology treatments in women at risk for treatment induced ovarian failure. The investigators will also assess and describe the emotional, reproductive and quality of life concerns of newly diagnosed cancer patients referred for fertility preservation and determine the physical, psychosocial and quality of life differences of cancer survivors who undergo fertility preservation in comparison to those who choose not to or are unsuccessful in their attempts to cryopreserve.

Protocol Methodology:

Women who are scheduled to undergo chemotherapy and/or radiation and present for fertility preservation consultation at The Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine will be recruited for this study. All recruited patients (including those who undergo cryopreservation of embryos, eggs or ovarian tissue, those who do not undergo cryopreservation of embryos, eggs or ovarian tissue, and those who are unable to undergo cryopreservation) will be evaluated at the following time points: T1: Before starting chemotherapy initial consultation for fertility preservation; T2: Pre oncology treatment (eg chemotherapy and/or radiation; T3: At six months to 1 year post chemotherapy; Patients will subsequently have annual follow up visit for 3 years. The study involves two components: 1) Assessment of biochemical and biophysical parameters of ovarian reserve. 2) Assessment of psychosocial, reproductive and quality of life concerns of these patients

The investigators will evaluate biochemical and biophysical parameters of ovarian reserve in these patients. Anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH), estradiol (E2) levels will be drawn. In addition, the ovaries will be examined and antral follicle counts and ovarian volume will be measured on the same days that the hormone levels are drawn (if appropriate). Subjects will be asked to keep a menstrual calendar diary from baseline (pre-chemotherapy) and for 1 year post chemotherapy.

In order to assess and describe the psychosocial, reproductive and quality of life concerns of these patients, a Quality of Life (QOL) survey will be completed pre and post chemotherapy at time points:

T1: At the time of pre-chemotherapy (initial consultation for fertility preservation).

T2: Pre chemotherapy/radiation treatment. Patients who have successful cryopreservation of embryos or eggs will be asked to complete the survey on the day of embryo or egg cryopreservation or before the start date of their initial chemotherapy treatment. Patients who do not have successful cryopreservation of embryos or eggs will be asked to complete the survey after receiving notification that the fertility preservation treatment is cancelled. Patients who do not choose to cryopreserve embryos or eggs will be asked to fill out the survey before the start date of their initial chemotherapy treatment. Participants will be mailed or given a survey instrument and the data collected either in person, by mail, or by telephone.

T3: At six months to 1 year post chemotherapy, patients will be asked to complete the final survey by phone or by mail. Systematic reminders (mail and phone) will be used to ensure return of the surveys. Each study survey should take approximately 40-55 minutes to complete. The domains assessed will include psychological functioning, reproductive and fertility preservation concerns, relationship satisfaction, and quality of life prior to and following potential fertility preservation and initial chemotherapy treatment for breast cancer. Participants do not have to respond to any question that they choose not to answer.

Study Instruments: Quality of Life (QOL) survey-

  1. Psychosocial History and Background Information Form
  2. Symptom Checklist (SCL)
  3. Center for Epidemiologic Studies-Depression (CES-D)
  4. Dyadic Adjustment Scale (DAS)
  5. The Reproductive Concerns Scale (RCS)
  6. Impact of Events Scale (IES)
  7. The Life Orientation Test (LOT-R)
  8. The Functional Assessment of Cancer Therapy-General

Data will be collected and analyzed. This new data will help us establish a better understanding of the effects of chemotherapy on total ovarian reserve and assist clinicians caring for patients of reproductive age in counseling these patients. The findings of study will also bring attention to the understudied area of fertility preservation and cancer survivorship. The investigators propose that by studying the short and long-term psychosocial impact of fertility preservation with comparison between those who undergo cryopreservation with those who do not, the investigators will be able to assess if psychosocial changes occur over time and identify points for future intervention.

Studietyp

Observationell

Inskrivning (Faktisk)

2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • New York
      • New York, New York, Förenta staterna, 10021
        • Ronald O. Perelmand and Claudia Cohen Center for Reproductive Medicine

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 45 år (Vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Kvinna

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Women scheduled to undergo chemotherpay/radiotherapy and are seeking fertility preservation at WCMC

Beskrivning

Inclusion Criteria:

  • Women ages 18-45
  • Women seeking fertility preservation at WCMC
  • Women who will undergo oncology treatments that will likely cause reduced fertility potential.

Exclusion Criteria:

  • Women who do not meet the inclusion criteria

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
AMH (anti-mullerian hormone) blood levels
Tidsram: Up to 3 years
To determine if fertility reserve is affected by oncology treatment.
Up to 3 years
Quality of life on the Dyadic Adjustment Scale
Tidsram: 3 years
To determine if there is any psychological impact of oncology treatment.
3 years

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Glenn Schattman, MD, Weill Medical College of Cornell University

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

30 maj 2017

Primärt slutförande (Faktisk)

12 mars 2021

Avslutad studie (Faktisk)

12 mars 2021

Studieregistreringsdatum

Först inskickad

9 juli 2015

Först inskickad som uppfyllde QC-kriterierna

3 augusti 2015

Första postat (Uppskatta)

5 augusti 2015

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

29 oktober 2021

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

27 oktober 2021

Senast verifierad

1 oktober 2021

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • 1301013407

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera